Literature DB >> 23276493

Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles.

Masaki Shimizu1, Yasuo Nakagishi, Akihiro Yachie.   

Abstract

To assess the serum interleukin (IL)-6 and IL-18 levels in patients with systemic juvenile idiopathic arthritis (s-JIA) and to identify the clinical features of patient subsets with different cytokine profiles, we analyzed the serum levels of IL-6 and IL-18 in patients with s-JIA and compared them with the clinical features of s-JIA. Eighteen patients were analyzed. IL-6 and IL-18 levels were quantified in serum by enzyme-linked immunosorbent assays. Interestingly, two distinct s-JIA patient subsets based on their serum IL-6 and IL-18 levels were identified: an IL-6 dominant and an IL-18 dominant. The serum IL-6 and IL-18 levels were consistent both at relapse and at the onset of s-JIA in each subset. The IL-6-dominant subset had a significantly greater number of joints with active disease and higher serum levels of matrix metalloproteinase-3, whereas the IL-18-dominant subset was more likely to develop macrophage activation syndrome (MAS). These findings indicate that two subsets of patients with s-JIA, one which is prone for arthritis and another with prone for MAS, can be identified on the basis of their serum IL-6 and IL-18 levels. These two subsets appear to be characterized by certain distinct clinical features.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23276493     DOI: 10.1016/j.cyto.2012.11.025

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  36 in total

1.  Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis.

Authors:  Peter A Nigrovic
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-17       Impact factor: 11.205

Review 2.  Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis.

Authors:  Lehn K Weaver; Edward M Behrens
Journal:  Curr Opin Rheumatol       Date:  2014-09       Impact factor: 5.006

3.  Weathering the storm: Improving therapeutic interventions for cytokine storm syndromes by targeting disease pathogenesis.

Authors:  Lehn K Weaver; Edward M Behrens
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-02-07

4.  Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus.

Authors:  Zachary Junga; Rodger Stitt; Christopher Tracy; Michael Keith
Journal:  BMJ Case Rep       Date:  2017-08-21

5.  IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome.

Authors:  Shima Yasin; Ndate Fall; Rachel A Brown; Maggie Henderlight; Scott W Canna; Charlotte Girard-Guyonvarc'h; Cem Gabay; Alexei A Grom; Grant S Schulert
Journal:  Rheumatology (Oxford)       Date:  2020-02-01       Impact factor: 7.580

Review 6.  New monogenic autoinflammatory diseases--a clinical overview.

Authors:  Scott W Canna; Raphaela Goldbach-Mansky
Journal:  Semin Immunopathol       Date:  2015-05-12       Impact factor: 9.623

Review 7.  From bench to bedside and back again: translational research in autoinflammation.

Authors:  Dirk Holzinger; Christoph Kessel; Alessia Omenetti; Marco Gattorno
Journal:  Nat Rev Rheumatol       Date:  2015-06-16       Impact factor: 20.543

Review 8.  Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart.

Authors:  Yvan Jamilloux; Mathieu Gerfaud-Valentin; Fabio Martinon; Alexandre Belot; Thomas Henry; Pascal Sève
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

Review 9.  The genetics of macrophage activation syndrome.

Authors:  Grant S Schulert; Randy Q Cron
Journal:  Genes Immun       Date:  2020-04-15       Impact factor: 2.676

Review 10.  Biomarkers in systemic juvenile idiopathic arthritis: a comparison with biomarkers in cryopyrin-associated periodic syndromes.

Authors:  Nanguneri Nirmala; Alexei Grom; Hermann Gram
Journal:  Curr Opin Rheumatol       Date:  2014-09       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.